Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CDX-1140 by Celldex Therapeutics for Endometrial Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
CDX-1140 by Celldex Therapeutics for Fallopian Tube Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
CDX-1140 by Celldex Therapeutics for Peritoneal Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
CDX-1140 by Celldex Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
CDX-1140 by Celldex Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
CDX-1140 is under clinical development by Celldex Therapeutics and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...